Literature DB >> 23713908

Cell therapy for lung diseases. Report from an NIH-NHLBI workshop, November 13-14, 2012.

Michael A Matthay1, Piero Anversa, Jahar Bhattacharya, Bruce K Burnett, Harold A Chapman, Joshua M Hare, Derek J Hei, Andrew M Hoffman, Stella Kourembanas, David H McKenna, Luis A Ortiz, Harald C Ott, William Tente, Bernard Thébaud, Bruce C Trapnell, Daniel J Weiss, Jason X-J Yuan, Carol J Blaisdell.   

Abstract

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health convened the Cell Therapy for Lung Disease Working Group on November 13-14, 2012, to review and formulate recommendations for future research directions. The workshop brought together investigators studying basic mechanisms and the roles of cell therapy in preclinical models of lung injury and pulmonary vascular disease, with clinical trial experts in cell therapy for cardiovascular diseases and experts from the NHLBI Production Assistance for Cell Therapy program. The purpose of the workshop was to discuss the current status of basic investigations in lung cell therapy, to identify some of the scientific gaps in current knowledge regarding the potential roles and mechanisms of cell therapy in the treatment of lung diseases, and to develop recommendations to the NHLBI and the research community on scientific priorities and practical steps that would lead to first-in-human trials of lung cell therapy.

Entities:  

Mesh:

Year:  2013        PMID: 23713908      PMCID: PMC3778734          DOI: 10.1164/rccm.201303-0522WS

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  35 in total

1.  Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury.

Authors:  Mohammad Naimul Islam; Shonit R Das; Memet T Emin; Michelle Wei; Li Sun; Kristin Westphalen; David J Rowlands; Sadiqa K Quadri; Sunita Bhattacharya; Jahar Bhattacharya
Journal:  Nat Med       Date:  2012-04-15       Impact factor: 53.440

2.  Mitochondrial transfer between cells can rescue aerobic respiration.

Authors:  Jeffrey L Spees; Scott D Olson; Mandolin J Whitney; Darwin J Prockop
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

3.  Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation.

Authors:  Konstantinos E Hatzistergos; Henry Quevedo; Behzad N Oskouei; Qinghua Hu; Gary S Feigenbaum; Irene S Margitich; Ramesh Mazhari; Andrew J Boyle; Juan P Zambrano; Jose E Rodriguez; Raul Dulce; Pradip M Pattany; David Valdes; Concepcion Revilla; Alan W Heldman; Ian McNiece; Joshua M Hare
Journal:  Circ Res       Date:  2010-07-29       Impact factor: 17.367

4.  Integrin α6β4 identifies an adult distal lung epithelial population with regenerative potential in mice.

Authors:  Harold A Chapman; Xiaopeng Li; Jonathan P Alexander; Alexis Brumwell; Walter Lorizio; Kevin Tan; Arnoud Sonnenberg; Ying Wei; Thiennu H Vu
Journal:  J Clin Invest       Date:  2011-06-23       Impact factor: 14.808

5.  Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection.

Authors:  Pooja A Kumar; Yuanyu Hu; Yusuke Yamamoto; Neo Boon Hoe; Tay Seok Wei; Dakai Mu; Yan Sun; Lim Siew Joo; Rania Dagher; Elisabeth M Zielonka; De Yun Wang; Bing Lim; Vincent T Chow; Christopher P Crum; Wa Xian; Frank McKeon
Journal:  Cell       Date:  2011-10-28       Impact factor: 41.582

6.  Lung-derived mesenchymal stromal cell post-transplantation survival, persistence, paracrine expression, and repair of elastase-injured lung.

Authors:  Andrew M Hoffman; Julia A Paxson; Melissa R Mazan; Airiel M Davis; Shivraj Tyagi; Shankar Murthy; Edward P Ingenito
Journal:  Stem Cells Dev       Date:  2011-07-06       Impact factor: 3.272

7.  A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.

Authors:  Joshua M Hare; Jay H Traverse; Timothy D Henry; Nabil Dib; Robert K Strumpf; Steven P Schulman; Gary Gerstenblith; Anthony N DeMaria; Ali E Denktas; Roger S Gammon; James B Hermiller; Mark A Reisman; Gary L Schaer; Warren Sherman
Journal:  J Am Coll Cardiol       Date:  2009-12-08       Impact factor: 24.094

8.  Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension.

Authors:  Changjin Lee; S Alex Mitsialis; Muhammad Aslam; Sally H Vitali; Eleni Vergadi; Georgios Konstantinou; Konstantinos Sdrimas; Angeles Fernandez-Gonzalez; Stella Kourembanas
Journal:  Circulation       Date:  2012-10-31       Impact factor: 29.690

Review 9.  Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing.

Authors:  Rebecca L Toonkel; Joshua M Hare; Michael A Matthay; Marilyn K Glassberg
Journal:  Am J Respir Crit Care Med       Date:  2013-07-15       Impact factor: 21.405

10.  Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension.

Authors:  Georg Hansmann; Angeles Fernandez-Gonzalez; Muhammad Aslam; Sally H Vitali; Thomas Martin; S Alex Mitsialis; Stella Kourembanas
Journal:  Pulm Circ       Date:  2012 Apr-Jun       Impact factor: 3.017

View more
  21 in total

Review 1.  MSC microvesicles for the treatment of lung disease: a new paradigm for cell-free therapy.

Authors:  Konstantinos Sdrimas; Stella Kourembanas
Journal:  Antioxid Redox Signal       Date:  2014-02-24       Impact factor: 8.401

Review 2.  Stem cells, cell therapies, and bioengineering in lung biology and diseases. Comprehensive review of the recent literature 2010-2012.

Authors:  Daniel J Weiss
Journal:  Ann Am Thorac Soc       Date:  2013-10

3.  An official American Thoracic Society workshop report: stem cells and cell therapies in lung biology and diseases.

Authors:  Daniel J Weiss; Daniel Chambers; Adam Giangreco; Armand Keating; Darrell Kotton; Peter I Lelkes; Darcy E Wagner; Darwin J Prockop
Journal:  Ann Am Thorac Soc       Date:  2015-04

Review 4.  Endogenous and exogenous cell-based pathways for recovery from acute respiratory distress syndrome.

Authors:  Jeffrey E Gotts; Michael A Matthay
Journal:  Clin Chest Med       Date:  2014-09-24       Impact factor: 2.878

Review 5.  The Robyn Barst Memorial Lecture: Differences between the fetal, newborn, and adult pulmonary circulations: relevance for age-specific therapies (2013 Grover Conference series).

Authors:  Steven H Abman; Christopher Baker; Jason Gien; Peter Mourani; Csaba Galambos
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

6.  Mesenchymal stromal cell-derived extracellular vesicle therapy prevents preeclamptic physiology through intrauterine immunomodulation†.

Authors:  Elizabeth S Taglauer; Angeles Fernandez-Gonzalez; Gareth R Willis; Monica Reis; Vincent Yeung; Xianlan Liu; S Alex Mitsialis; Stella Kourembanas
Journal:  Biol Reprod       Date:  2021-02-11       Impact factor: 4.285

7.  Resolution of pulmonary edema. Thirty years of progress.

Authors:  Michael A Matthay
Journal:  Am J Respir Crit Care Med       Date:  2014-06-01       Impact factor: 21.405

8.  Hypoxia enhances differentiation of mouse embryonic stem cells into definitive endoderm and distal lung cells.

Authors:  Pimchanok Pimton; Shimon Lecht; Collin T Stabler; Gregg Johannes; Edward S Schulman; Peter I Lelkes
Journal:  Stem Cells Dev       Date:  2014-10-27       Impact factor: 3.272

9.  Extracellular Vesicles Protect the Neonatal Lung from Hyperoxic Injury through the Epigenetic and Transcriptomic Reprogramming of Myeloid Cells.

Authors:  Gareth R Willis; Monica Reis; Ali Hashemi Gheinani; Angeles Fernandez-Gonzalez; Elizabeth S Taglauer; Vincent Yeung; Xianlan Liu; Maria Ericsson; Eric Haas; S Alex Mitsialis; Stella Kourembanas
Journal:  Am J Respir Crit Care Med       Date:  2021-12-15       Impact factor: 21.405

10.  Host Defense against Klebsiella pneumoniae Pneumonia Is Augmented by Lung-Derived Mesenchymal Stem Cells.

Authors:  Tirumalai Rangasamy; Laxman Ghimire; Liliang Jin; John Le; Sivakumar Periasamy; Sagar Paudel; Shanshan Cai; Samithamby Jeyaseelan
Journal:  J Immunol       Date:  2021-08-02       Impact factor: 5.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.